Avalyn Pharma (AVLN)
Develops inhaled pirfenidone and nintedanib candidates for pulmonary fibrosis.
$29.67
After hours−0.12 (−0.40%)
At close$29.79(−8.20%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 99.60% | 44.15M shares | |
|---|---|---|---|
| 94 holders · as of Jun 30, 2026 | |||
| Other | 0.40% | 179.1K shares | |
| remainder | |||
44.33M company shares as of Aug 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
13F, as of Jun 30, 2026
94 holders · 44.15M shares · 94 new positions · 94 increased · 0 reduced · 0 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 5.84M | 13.16% | +5.84Mnew | Aug 13, 2026 |
| Novo Holdings A/S | 3.88M | 8.76% | +3.88Mnew | Aug 14, 2026 |
| Sr One Capital Management, LP | 3.31M | 7.46% | +3.31Mnew | Aug 12, 2026 |
| Perceptive Advisors LLC | 2.68M | 6.03% | +2.68Mnew | Aug 14, 2026 |
| Suvretta Capital Management, LLC | 2.50M | 5.65% | +2.50Mnew | Aug 14, 2026 |
| NVP Associates, LLC | 2.27M | 5.12% | +2.27Mnew | Aug 7, 2026 |
| Wellington Management Group LLP | 2.20M | 4.97% | +2.20Mnew | Aug 14, 2026 |
| Price T Rowe Associates Inc /MD/ | 1.74M | 3.91% | +1.74Mnew | Aug 14, 2026 |
13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Form 4
Latest trades
Nothing filed in the last 12 months.
House and Senate disclosures
Not reported.